{"transactions":[{"id":686452,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":23218,"kind":"person","name":"Atkins Susan E.","position":1,"cik":"0002111494","reported_name":"Atkins Susan E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T23:00:43.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 33% of the underlying shares on the first anniversary of the grant date, and the remaining shares vest in two equal annual installments thereafter on the second and third anniversary of the grant date, subject to the Reporting Person's continuous service with the Issuer through the relevant vesting dates."}],"balance_after":17000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-097388","document":"tm2623296-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926097388/tm2623296-2_4seq1.xml","form_type":"4"}},{"id":733223,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-06-18T00:01:09.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":212,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-075302","document":"tm2618120-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926075302/tm2618120-4_4seq1.xml","form_type":"4"}},{"id":733222,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-18T00:01:09.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":26838,"source":{"system":"sec-edgar","filing":"0001104659-26-075302","document":"tm2618120-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926075302/tm2618120-4_4seq1.xml","form_type":"4"}},{"id":733825,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-06-18T00:00:47.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":212,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-075301","document":"tm2618120-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926075301/tm2618120-3_4seq1.xml","form_type":"4"}},{"id":733824,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-18T00:00:47.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":26335,"source":{"system":"sec-edgar","filing":"0001104659-26-075301","document":"tm2618120-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926075301/tm2618120-3_4seq1.xml","form_type":"4"}},{"id":733221,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-06-18T00:00:27.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":212,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-075300","document":"tm2618120-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926075300/tm2618120-2_4seq1.xml","form_type":"4"}},{"id":733220,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-18T00:00:27.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":26210,"source":{"system":"sec-edgar","filing":"0001104659-26-075300","document":"tm2618120-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926075300/tm2618120-2_4seq1.xml","form_type":"4"}},{"id":734165,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-06-18T00:00:06.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1313,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-26-075298","document":"tm2618120-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926075298/tm2618120-1_4seq1.xml","form_type":"4"}},{"id":734164,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-06-18T00:00:06.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":69817,"source":{"system":"sec-edgar","filing":"0001104659-26-075298","document":"tm2618120-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926075298/tm2618120-1_4seq1.xml","form_type":"4"}},{"id":765332,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-22T23:02:45.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":52500,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-26-065841","document":"tm2615413-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065841/tm2615413-4_4seq1.xml","form_type":"4"}},{"id":765331,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-22T23:02:45.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":6845,"price":1.085,"value":7426.825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.105. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":26175,"source":{"system":"sec-edgar","filing":"0001104659-26-065841","document":"tm2615413-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065841/tm2615413-4_4seq1.xml","form_type":"4"}},{"id":765330,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-22T23:02:45.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":33020,"source":{"system":"sec-edgar","filing":"0001104659-26-065841","document":"tm2615413-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065841/tm2615413-4_4seq1.xml","form_type":"4"}},{"id":765329,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-22T23:02:11.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":52500,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-26-065839","document":"tm2615413-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065839/tm2615413-3_4seq1.xml","form_type":"4"}},{"id":765328,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-22T23:02:11.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":6560,"price":1.084,"value":7111.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.09.  The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":26803,"source":{"system":"sec-edgar","filing":"0001104659-26-065839","document":"tm2615413-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065839/tm2615413-3_4seq1.xml","form_type":"4"}},{"id":765327,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-22T23:02:11.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":33363,"source":{"system":"sec-edgar","filing":"0001104659-26-065839","document":"tm2615413-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926065839/tm2615413-3_4seq1.xml","form_type":"4"}},{"id":765682,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-22T23:01:40.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":52500,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-26-065838","document":"tm2615413-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926065838/tm2615413-2_4seq1.xml","form_type":"4"}},{"id":765681,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-22T23:01:40.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":6845,"price":1.085,"value":7426.825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.105. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":26300,"source":{"system":"sec-edgar","filing":"0001104659-26-065838","document":"tm2615413-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926065838/tm2615413-2_4seq1.xml","form_type":"4"}},{"id":765680,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-22T23:01:40.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":33145,"source":{"system":"sec-edgar","filing":"0001104659-26-065838","document":"tm2615413-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926065838/tm2615413-2_4seq1.xml","form_type":"4"}},{"id":766004,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-05-22T23:00:13.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":49758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":149274,"derivative":{"underlying":"Common Stock","underlying_shares":49758},"source":{"system":"sec-edgar","filing":"0001104659-26-065836","document":"tm2615413-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926065836/tm2615413-1_4seq1.xml","form_type":"4"}},{"id":766003,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-05-22T23:00:13.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":19419,"price":1.087,"value":21108.453,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.105. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":69598,"source":{"system":"sec-edgar","filing":"0001104659-26-065836","document":"tm2615413-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926065836/tm2615413-1_4seq1.xml","form_type":"4"}},{"id":766002,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-05-22T23:00:13.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":49758,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":89017,"source":{"system":"sec-edgar","filing":"0001104659-26-065836","document":"tm2615413-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926065836/tm2615413-1_4seq1.xml","form_type":"4"}},{"id":788530,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-05-07T23:01:33.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-26-057367","document":"tm2613630-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926057367/tm2613630-4_4seq1.xml","form_type":"4"}},{"id":788529,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-05-07T23:01:33.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":39259,"source":{"system":"sec-edgar","filing":"0001104659-26-057367","document":"tm2613630-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926057367/tm2613630-4_4seq1.xml","form_type":"4"}},{"id":788407,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-07T23:01:04.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-057366","document":"tm2613630-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926057366/tm2613630-3_4seq1.xml","form_type":"4"}},{"id":788406,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T23:01:04.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15645,"source":{"system":"sec-edgar","filing":"0001104659-26-057366","document":"tm2613630-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926057366/tm2613630-3_4seq1.xml","form_type":"4"}},{"id":788205,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-07T23:00:39.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-057365","document":"tm2613630-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926057365/tm2613630-2_4seq1.xml","form_type":"4"}},{"id":788204,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-07T23:00:39.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15520,"source":{"system":"sec-edgar","filing":"0001104659-26-057365","document":"tm2613630-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926057365/tm2613630-2_4seq1.xml","form_type":"4"}},{"id":788207,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-07T23:00:12.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-057364","document":"tm2613630-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926057364/tm2613630-1_4seq1.xml","form_type":"4"}},{"id":788206,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-07T23:00:12.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15863,"source":{"system":"sec-edgar","filing":"0001104659-26-057364","document":"tm2613630-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926057364/tm2613630-1_4seq1.xml","form_type":"4"}},{"id":841672,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:05:59.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1532,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-26-028722","document":"tm268882-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926028722/tm268882-4_4seq1.xml","form_type":"4"}},{"id":841671,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:05:59.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":false,"shares":164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":488,"derivative":{"underlying":"Common Stock","underlying_shares":164},"source":{"system":"sec-edgar","filing":"0001104659-26-028722","document":"tm268882-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926028722/tm268882-4_4seq1.xml","form_type":"4"}},{"id":841670,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-17T00:05:59.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":21259,"source":{"system":"sec-edgar","filing":"0001104659-26-028722","document":"tm268882-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926028722/tm268882-4_4seq1.xml","form_type":"4"}},{"id":841669,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-17T00:05:59.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":true,"shares":164,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":21040,"source":{"system":"sec-edgar","filing":"0001104659-26-028722","document":"tm268882-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926028722/tm268882-4_4seq1.xml","form_type":"4"}},{"id":841409,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:04:36.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":247,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-028721","document":"tm268882-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926028721/tm268882-3_4seq1.xml","form_type":"4"}},{"id":841408,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:04:36.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":97,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-26-028721","document":"tm268882-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926028721/tm268882-3_4seq1.xml","form_type":"4"}},{"id":841407,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-17T00:04:36.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6645,"source":{"system":"sec-edgar","filing":"0001104659-26-028721","document":"tm268882-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926028721/tm268882-3_4seq1.xml","form_type":"4"}},{"id":841406,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-17T00:04:36.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6610,"source":{"system":"sec-edgar","filing":"0001104659-26-028721","document":"tm268882-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926028721/tm268882-3_4seq1.xml","form_type":"4"}},{"id":840971,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:03:28.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":247,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-028720","document":"tm268882-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028720/tm268882-2_4seq1.xml","form_type":"4"}},{"id":840970,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:03:28.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":97,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-26-028720","document":"tm268882-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028720/tm268882-2_4seq1.xml","form_type":"4"}},{"id":840969,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-17T00:03:28.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6863,"source":{"system":"sec-edgar","filing":"0001104659-26-028720","document":"tm268882-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028720/tm268882-2_4seq1.xml","form_type":"4"}},{"id":840968,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-17T00:03:28.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6828,"source":{"system":"sec-edgar","filing":"0001104659-26-028720","document":"tm268882-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028720/tm268882-2_4seq1.xml","form_type":"4"}},{"id":840967,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:01:16.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":247,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-028718","document":"tm268882-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028718/tm268882-1_4seq1.xml","form_type":"4"}},{"id":840966,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:01:16.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":97,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-26-028718","document":"tm268882-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028718/tm268882-1_4seq1.xml","form_type":"4"}},{"id":840965,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-17T00:01:16.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6520,"source":{"system":"sec-edgar","filing":"0001104659-26-028718","document":"tm268882-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028718/tm268882-1_4seq1.xml","form_type":"4"}},{"id":840964,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-17T00:01:16.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6485,"source":{"system":"sec-edgar","filing":"0001104659-26-028718","document":"tm268882-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926028718/tm268882-1_4seq1.xml","form_type":"4"}},{"id":940701,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":28185,"kind":"person","name":"Laumas Sandeep","position":1,"cik":"0001721664","reported_name":"Laumas Sandeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T00:09:53.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002981","document":"tm262917-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926002981/tm262917-7_4seq1.xml","form_type":"4"}},{"id":940864,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":38121,"kind":"person","name":"MILLER MICHAEL PATRICK","position":1,"cik":"0001236514","reported_name":"MILLER MICHAEL PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T00:02:53.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002976","document":"tm262917-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236514/000110465926002976/tm262917-3_4seq1.xml","form_type":"4"}},{"id":940700,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":69040,"kind":"person","name":"Bray June","position":1,"cik":"0001845487","reported_name":"Bray June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T00:01:13.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002975","document":"tm262917-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926002975/tm262917-2_4seq1.xml","form_type":"4"}},{"id":941025,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T00:00:25.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002973","document":"tm262917-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465926002973/tm262917-1_4seq1.xml","form_type":"4"}},{"id":940736,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":2455,"kind":"person","name":"Patni Rajiv","position":1,"cik":"0001616200","reported_name":"Patni Rajiv","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T19:08:04.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002980","document":"tm262917-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616200/000110465926002980/tm262917-6_4seq1.xml","form_type":"4"}},{"id":940837,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":16509,"kind":"person","name":"MUELLER PETER","position":1,"cik":"0001256126","reported_name":"MUELLER PETER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T19:06:49.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002979","document":"tm262917-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256126/000110465926002979/tm262917-5_4seq1.xml","form_type":"4"}},{"id":940727,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":69499,"kind":"person","name":"Votruba Michal","position":1,"cik":"0001653967","reported_name":"Votruba Michal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T19:05:32.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002978","document":"tm262917d4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653967/000110465926002978/tm262917d4_4seq1.xml","form_type":"4"}},{"id":949849,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T01:02:17.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":70282,"derivative":{"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001104659-26-000838","document":"tm261931-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926000838/tm261931-4_4seq1.xml","form_type":"4"}},{"id":950761,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T01:01:25.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":70282,"derivative":{"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001104659-26-000837","document":"tm261931-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926000837/tm261931-3_4seq1.xml","form_type":"4"}},{"id":951635,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T01:00:47.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":199032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":200783,"derivative":{"underlying":"Common Stock","underlying_shares":199032},"source":{"system":"sec-edgar","filing":"0001104659-26-000835","document":"tm261931-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926000835/tm261931-2_4seq1.xml","form_type":"4"}},{"id":949845,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T01:00:11.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":70282,"derivative":{"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001104659-26-000834","document":"tm261931-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926000834/tm261931-1_4seq1.xml","form_type":"4"}},{"id":969520,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:02:47.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1751,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-25-121304","document":"tm2533410-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925121304/tm2533410-4_4seq1.xml","form_type":"4"}},{"id":969519,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:02:47.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":false,"shares":164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":652,"derivative":{"underlying":"Common Stock","underlying_shares":164},"source":{"system":"sec-edgar","filing":"0001104659-25-121304","document":"tm2533410-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925121304/tm2533410-4_4seq1.xml","form_type":"4"}},{"id":969518,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-12-16T01:02:47.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20876,"source":{"system":"sec-edgar","filing":"0001104659-25-121304","document":"tm2533410-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925121304/tm2533410-4_4seq1.xml","form_type":"4"}},{"id":969517,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-12-16T01:02:47.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":true,"shares":164,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20657,"source":{"system":"sec-edgar","filing":"0001104659-25-121304","document":"tm2533410-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925121304/tm2533410-4_4seq1.xml","form_type":"4"}},{"id":969197,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:01:59.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":282,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-121303","document":"tm2533410-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925121303/tm2533410-3_4seq1.xml","form_type":"4"}},{"id":969196,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:01:59.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":130,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-121303","document":"tm2533410-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925121303/tm2533410-3_4seq1.xml","form_type":"4"}},{"id":969195,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-16T01:01:59.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6577,"source":{"system":"sec-edgar","filing":"0001104659-25-121303","document":"tm2533410-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925121303/tm2533410-3_4seq1.xml","form_type":"4"}},{"id":969194,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-16T01:01:59.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6542,"source":{"system":"sec-edgar","filing":"0001104659-25-121303","document":"tm2533410-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925121303/tm2533410-3_4seq1.xml","form_type":"4"}},{"id":968813,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:01:33.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":282,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-121302","document":"tm2533410-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121302/tm2533410-2_4seq1.xml","form_type":"4"}},{"id":968812,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:01:33.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":130,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-121302","document":"tm2533410-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121302/tm2533410-2_4seq1.xml","form_type":"4"}},{"id":968811,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-16T01:01:33.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6795,"source":{"system":"sec-edgar","filing":"0001104659-25-121302","document":"tm2533410-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121302/tm2533410-2_4seq1.xml","form_type":"4"}},{"id":968810,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-16T01:01:33.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6760,"source":{"system":"sec-edgar","filing":"0001104659-25-121302","document":"tm2533410-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121302/tm2533410-2_4seq1.xml","form_type":"4"}},{"id":968809,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:00:15.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":282,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-121300","document":"tm2533410-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121300/tm2533410-1_4seq1.xml","form_type":"4"}},{"id":968808,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:00:15.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":130,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-121300","document":"tm2533410-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121300/tm2533410-1_4seq1.xml","form_type":"4"}},{"id":968807,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T01:00:15.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6452,"source":{"system":"sec-edgar","filing":"0001104659-25-121300","document":"tm2533410-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121300/tm2533410-1_4seq1.xml","form_type":"4"}},{"id":968806,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T01:00:15.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6417,"source":{"system":"sec-edgar","filing":"0001104659-25-121300","document":"tm2533410-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121300/tm2533410-1_4seq1.xml","form_type":"4"}},{"id":1009621,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-11-04T01:00:23.000Z","date":"2025-10-31","kind":"exercise","planned":false,"acquired":false,"shares":1694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1694},"source":{"system":"sec-edgar","filing":"0001104659-25-105760","document":"tm2530101-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925105760/tm2530101-1_4seq1.xml","form_type":"4"}},{"id":1009620,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T01:00:23.000Z","date":"2025-10-31","kind":"exercise","planned":false,"acquired":true,"shares":1694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20317,"source":{"system":"sec-edgar","filing":"0001104659-25-105760","document":"tm2530101-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925105760/tm2530101-1_4seq1.xml","form_type":"4"}},{"id":1029299,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-10-01T23:00:03.000Z","date":"2025-09-30","kind":"exercise","planned":false,"acquired":false,"shares":1694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":1694,"derivative":{"underlying":"Common Stock","underlying_shares":1694},"source":{"system":"sec-edgar","filing":"0001104659-25-095739","document":"tm2527731-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925095739/tm2527731-1_4seq1.xml","form_type":"4"}},{"id":1029298,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-01T23:00:03.000Z","date":"2025-09-30","kind":"exercise","planned":false,"acquired":true,"shares":1694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":18623,"source":{"system":"sec-edgar","filing":"0001104659-25-095739","document":"tm2527731-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925095739/tm2527731-1_4seq1.xml","form_type":"4"}},{"id":1039387,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:05:59.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1970,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-25-090518","document":"tm2526247-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925090518/tm2526247-4_4seq1.xml","form_type":"4"}},{"id":1039386,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:05:59.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":false,"shares":163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":816,"derivative":{"underlying":"Common Stock","underlying_shares":163},"source":{"system":"sec-edgar","filing":"0001104659-25-090518","document":"tm2526247-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925090518/tm2526247-4_4seq1.xml","form_type":"4"}},{"id":1039385,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-09-16T23:05:59.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20493,"source":{"system":"sec-edgar","filing":"0001104659-25-090518","document":"tm2526247-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925090518/tm2526247-4_4seq1.xml","form_type":"4"}},{"id":1039384,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-09-16T23:05:59.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":true,"shares":163,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20274,"source":{"system":"sec-edgar","filing":"0001104659-25-090518","document":"tm2526247-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925090518/tm2526247-4_4seq1.xml","form_type":"4"}},{"id":1039230,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:04:35.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":317,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-090517","document":"tm2526247-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925090517/tm2526247-3_4seq1.xml","form_type":"4"}},{"id":1039229,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:04:35.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":163,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-090517","document":"tm2526247-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925090517/tm2526247-3_4seq1.xml","form_type":"4"}},{"id":1039228,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-16T23:04:35.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6509,"source":{"system":"sec-edgar","filing":"0001104659-25-090517","document":"tm2526247-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925090517/tm2526247-3_4seq1.xml","form_type":"4"}},{"id":1039227,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-16T23:04:35.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6474,"source":{"system":"sec-edgar","filing":"0001104659-25-090517","document":"tm2526247-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925090517/tm2526247-3_4seq1.xml","form_type":"4"}},{"id":1038990,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:02:50.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":317,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-090516","document":"tm2526247-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090516/tm2526247-2_4seq1.xml","form_type":"4"}},{"id":1038989,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:02:50.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":163,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-090516","document":"tm2526247-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090516/tm2526247-2_4seq1.xml","form_type":"4"}},{"id":1038988,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-16T23:02:50.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6727,"source":{"system":"sec-edgar","filing":"0001104659-25-090516","document":"tm2526247-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090516/tm2526247-2_4seq1.xml","form_type":"4"}},{"id":1038987,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-16T23:02:50.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6692,"source":{"system":"sec-edgar","filing":"0001104659-25-090516","document":"tm2526247-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090516/tm2526247-2_4seq1.xml","form_type":"4"}},{"id":1038985,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:00:59.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":317,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-090514","document":"tm2526247-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090514/tm2526247-1_4seq1.xml","form_type":"4"}},{"id":1038984,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:00:59.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":163,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-090514","document":"tm2526247-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090514/tm2526247-1_4seq1.xml","form_type":"4"}},{"id":1038983,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-09-16T23:00:59.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6384,"source":{"system":"sec-edgar","filing":"0001104659-25-090514","document":"tm2526247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090514/tm2526247-1_4seq1.xml","form_type":"4"}},{"id":1038982,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-09-16T23:00:59.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6349,"source":{"system":"sec-edgar","filing":"0001104659-25-090514","document":"tm2526247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925090514/tm2526247-1_4seq1.xml","form_type":"4"}},{"id":1051442,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-09-02T23:00:14.000Z","date":"2025-08-31","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":3387,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-086528","document":"tm2524989-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925086528/tm2524989-1_4seq1.xml","form_type":"4"}},{"id":1051441,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-02T23:00:14.000Z","date":"2025-08-31","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":16930,"source":{"system":"sec-edgar","filing":"0001104659-25-086528","document":"tm2524989-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925086528/tm2524989-1_4seq1.xml","form_type":"4"}},{"id":1074335,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-08-06T00:02:09.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-25-074372","document":"tm2522669-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925074372/tm2522669-4_4seq1.xml","form_type":"4"}},{"id":1073879,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37105,"kind":"person","name":"Rodriguez Javier","position":1,"cik":"0001847919","reported_name":"Rodriguez Javier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-08-06T00:01:28.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-25-074371","document":"tm2522669-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925074371/tm2522669-3_4seq1.xml","form_type":"4"}},{"id":1073878,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37104,"kind":"person","name":"Yocca Frank","position":1,"cik":"0001733272","reported_name":"Yocca Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-08-06T00:00:51.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-25-074370","document":"tm2522669-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925074370/tm2522669-2_4seq1.xml","form_type":"4"}},{"id":1074645,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-08-06T00:00:14.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":18000,"derivative":{"underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-25-074369","document":"tm2522669-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925074369/tm2522669-1_4seq1.xml","form_type":"4"}},{"id":1078408,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-31T20:15:20.000Z","date":"2025-07-31","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":5080,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-072701","document":"tm2521524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925072701/tm2521524-1_4seq1.xml","form_type":"4"}},{"id":1078407,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-31T20:15:20.000Z","date":"2025-07-31","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15237,"source":{"system":"sec-edgar","filing":"0001104659-25-072701","document":"tm2521524-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925072701/tm2521524-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2025-07-31T20:15:20.000000Z,1078407"}